Cll Global Research Foundation
- Assets
- $12.0m
- Revenue
- $2.5m
- Investments
- $0.0
- Employees
- 0
- Location
- Houston, TX
- Founding
- 11/2004
- Data as of
- 12/2023
- EIN
- 88-0517430
Organization Overview
Cll Global Research Foundation is located in Houston, TX. The organization was established in 2004. According to its NTEE Classification (H30) the organization is classified as: Cancer Research, under the broad grouping of Medical Research and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Cll Global Research Foundation is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2023, Cll Global Research Foundation generated $2.5m in total revenue. This represents relatively stable growth, over the past 8 years the organization has increased revenue by an average of 1.5% each year. All expenses for the organization totaled $3.1m during the year ending 12/2023. While expenses have increased by 7.8% per year over the past 8 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Since 2016, Cll Global Research Foundation has awarded 25 individual grants totaling $14,090,907. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2023
Describe the Organization's Mission:
Part 3 - Line 1
TO ACCELERATE PROGRESS TOWARD THE CONTROL AND CURE OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL).
Describe the Organization's Program Activity:
Part 3 - Line 4a
RESEARCH GRANTS: THE CLL GLOBAL RESEARCH FOUNDATION'S PRIMARY ACTIVITY IS TO ACCELERATE RESEARCH. THE NEED IS URGENT TO ACCELERATE PROMISING, UNTAPPED AREAS OF RESEARCH. CLL GLOBAL PROVIDES GRANTS THROUGH SEVERAL MECHANISMS TO FUND NOVEL, PATIENT-ORIENTED CONCEPTS. THE INTENTION IS TO FUND THE BEST CLL SCIENCE IN THE WORLD. IN PARTICULAR, CLL GLOBAL TARGETS MONOCLONAL ANTIBODIES, PROGNOSTIC FACTORS, VACCINES & GENE THERAPY, CLL SURVIVAL PATHWAY, GENETICS, MOLECULAR TARGETS, AND DRUG DEVELOPMENT. CONTINUED ON SCHEDULE O A SCIENTIFIC ADVISORY BOARD (SAB) DEVELOPS THE RESEARCH PRIORITIES AND OVERSEES THE DEVELOPMENT AND IMPLEMENTATION OF THE SUBMISSION, EVALUATION AND FUNDING PROCESS FOR GRANT APPLICATION CYCLES. SAB MEMBERS HAVE EXTENSIVE EXPERIENCE IN TREATING CLL PATIENTS, DEVELOPING NEW DRUGS AND OTHER TOOLS, AND STUDYING VARIOUS ASPECTS OF THE DISEASE. THE RESEARCH GRANT SECTION ALSO ALLOWS SUPPORT OF POSTDOCTORAL FELLOWS CONDUCTING A CLL-SPECIFIC PROJECT. IN 2023, CLL GLOBAL AWARDED NEW RESEARCH/INDIVIDUAL GRANTS RANGING FROM $100,000-$250,000. APPLICANTS INITIALLY SUBMIT PROPOSALS FOR UP TO $110,000 IN FUNDING FOR ONE YEAR. APPLICANTS IDENTIFY PROJECT MILESTONES. UPON DEMONSTRATION OF SUFFICIENT PROGRESS, INVESTIGATORS WILL BE CONSIDERED FOR A SECOND YEAR OF FUNDING. FOR ACCOUNTING PURPOSES, CLL GLOBAL EXPENSES GRANTS AT THE TIME OF COMPLETION OF A SPONSORED RESEARCH AGREEMENT.
ALLIANCE: THE US/EUROPEAN ALLIANCE FOR THE THERAPY OF CLL (ALLIANCE) IS COMPRISED OF 25 INDIVIDUALS FROM THE UNITED STATES AND EUROPE, REPRESENTING THE WORLD'S EXPERTS IN CLL RESEARCH. THE MEMBERS ARE DIVIDED INTO WORKING GROUPS FOCUSING ON ONE OF FIVE BIG IDEAS IN CLL RESEARCH (NEW DRUGS, GENE/VACCINE THERAPY, GENETICS, CLL-STROMAL INTERACTIONS, TRANSPLANT/IMMUNE RECONSTITUTION). THE ALLIANCE WAS BUILT TO ENCOURAGE CLOSE COLLABORATION WITHIN AND AMONG WORKING GROUPS. AS SUCH, MEETINGS ARE HELD TO BRING INVESTIGATORS TOGETHER TO COLLABORATE.
EDUCATION: CLL GLOBAL RESEARCH FOUNDATION HOSTS ANNUAL INTERACTIVE PATIENT EDUCATION EVENTS WHERE CLL PATIENTS LEARN ABOUT EMERGING THERAPIES, CURRENT TREATMENT OPTIONS AND SUPPORT RESOURCES FROM LEADING CLL EXPERTS. BOTH VIRTUAL AND IN-PERSON EVENTS WERE HELD IN 2023.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Michael J Keating Founding Director | OfficerTrustee | 2 | $0 |
William Wierda President & CEO | OfficerTrustee | 4 | $14,531 |
Phyllis Cohen Director | Trustee | 1 | $0 |
Richard Evans Director | Trustee | 1 | $0 |
Louis Katopodis Director | Trustee | 1 | $0 |
Diane Lee Kraitman Director | Trustee | 1 | $0 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $2,469,879 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $2,469,879 |
| Total Program Service Revenue | $0 |
| Investment income | $296,996 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | -$231,266 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $2,535,609 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $2,732,011 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $100,000 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $60,000 |
| Compensation of current officers, directors, key employees. | $10,800 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $20,000 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $0 |
| Payroll taxes | $0 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $0 |
| Fees for services: Accounting | $19,532 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $13,149 |
| Fees for services: Other | $7,255 |
| Advertising and promotion | $0 |
| Office expenses | $15,701 |
| Information technology | $39,493 |
| Royalties | $0 |
| Occupancy | $0 |
| Travel | $56,006 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $63,426 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $0 |
| Insurance | $3,016 |
| All other expenses | $0 |
| Total functional expenses | $3,129,589 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $2,540,044 |
| Savings and temporary cash investments | $399,559 |
| Pledges and grants receivable | $504,594 |
| Accounts receivable, net | $0 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $4,500 |
| Net Land, buildings, and equipment | $0 |
| Investments—publicly traded securities | $8,570,549 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $0 |
| Total assets | $12,019,246 |
| Accounts payable and accrued expenses | $34,852 |
| Grants payable | $2,842,006 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $2,876,858 |
| Net assets without donor restrictions | $8,637,794 |
| Net assets with donor restrictions | $504,594 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $12,019,246 |
Grants Awarded
Over the last fiscal year, Cll Global Research Foundation has awarded $2,732,011 in support to 3 organizations.
| Grant Recipient | Amount |
|---|---|
UT MD ANDERSON CANCER CENTER PURPOSE: CLL research grant | $2,267,011 |
FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH PURPOSE: CLL research grant | $115,000 |
OHIO STATE UNIVERSITY PURPOSE: CLL research grant | $350,000 |